Literature DB >> 23975358

Immunogenicity, the elephant in the room. Comment on "Drug levels, anti-drug antibodies and clinical efficacy of the anti-TNFα biologics in rheumatic diseases".

John Pixley1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23975358     DOI： 10.1007/s10067-013-2364-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  6 in total

1.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.

Authors:  Daniel E Furst; Edward Clark Keystone; Alexander K So; Jürgen Braun; Ferry C Breedveld; Gerd R Burmester; Fabrizio De Benedetti; Thomas Dörner; Paul Emery; Roy Fleischmann; Allan Gibofsky; J R Kalden; Arthur Kavanaugh; Bruce Kirkham; Philip Mease; A Rubbert-Roth; Joachim Sieper; Nora G Singer; Josef S Smolen; Piet L C M Van Riel; Michael H Weisman; Kevin L Winthrop
Journal:  Ann Rheum Dis       Date:  2013-04       Impact factor: 19.103

Review 2.  Optimizing use of tumor necrosis factor inhibitors in the management of immune-mediated inflammatory diseases.

Authors:  Brian Bressler; Boulos Haraoui; Edward Keystone; Alessandro Sette
Journal:  J Rheumatol Suppl       Date:  2010-05

3.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Authors:  Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

4.  Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.

Authors:  M K de Vries; I E van der Horst-Bruinsma; M T Nurmohamed; L A Aarden; S O Stapel; M J L Peters; J C van Denderen; B A C Dijkmans; G J Wolbink
Journal:  Ann Rheum Dis       Date:  2008-03-28       Impact factor: 19.103

5.  Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis.

Authors:  Helen G Haggerty; Mark A Abbott; Timothy P Reilly; Deborah A DeVona; Carol R Gleason; Lee Tay; Robert Dodge; Richard Aranda
Journal:  J Rheumatol       Date:  2007-11-15       Impact factor: 4.666

6.  Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study).

Authors:  Jeffrey Kaine; Geoffrey Gladstein; Ingrid Strusberg; Manuel Robles; Ingrid Louw; Sheila Gujrathi; Ramesh Pappu; Ingrid Delaet; Miranda Pans; Charles Ludivico
Journal:  Ann Rheum Dis       Date:  2011-09-13       Impact factor: 19.103
  6 in total
  1 in total

1.  Anti-infliximab antibodies and clinical response in noninfectious uveitis and scleritis patients treated with infliximab: A retrospective review.

Authors:  Lianna Valdes; Jacob T Cox; Janine Yang; Gayatri Susarla; Samuel Han; George N Papaliodis; Lucia Sobrin
Journal:  Am J Ophthalmol Case Rep       Date:  2022-06-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.